Inhibition of drug binding to human serum albumin by cholecystographic agents.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Il Farmaco

• Publication date

  2003-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-827X(03)00148-4PMID 13679185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid screening of small ligand affinity to human serum albumin by an optical biosensor.

  2003cited by this paper
• High-performance affinity chromatography: a powerful tool for studying serum protein binding.

  2002cited by this paper
• Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance.

  2002cited by this paper
• Oral Cholecystographic Agents and the Thyroid

  2001cited by this paper
• Implementing surface plasmon resonance biosensors in drug discovery.

  2000cited by this paper
• New approaches for the analysis of molecular recognition using the IAsys evanescent wave biosensor

  1998cited by this paper
• Stereospecific and competitive binding of drugs to human serum albumin: a difference circular dichroism approach.

  1995cited by this paper
• All About Albumin: Biochemistry, Genetics, and Medical Applications

  1995cited by this paper
• Enantioselective high-performance liquid affinity chromatography as a probe of ligand-biopolymer interactions: an overview of a different use for high-performance liquid chromatographic chiral stationary phases

  1994cited by this paper
• The resonant mirror: a novel optical sensor for direct sensing of biomolecular interactions part II: applications

  1993cited by this paper
• The resonant mirror: a novel optical biosensor for direct sensing of biomolecular interactions Part I: Principle of operation and associated instrumentation

  1992cited by this paper
• Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology.

  1991cited by this paper
• Conformational changes in human serum albumin induced by ligand binding.

  1990cited by this paper
• Stereochemical features of 1,4-benzodiazepin-2-ones bound to human serum albumin: difference CD and UV studies.

  1990cited by this paper
• Fluorimetric analysis of the binding of warfarin to human serum albumin. Equilibrium and kinetic study.

  1982cited by this paper
• Molecular aspects of ligand binding to serum albumin.

  1981cited by this paper
• Cholecystographic agents and drug binding to plasma albumin.

  1980cited by this paper
• The characterization of two specific drug binding sites on human serum albumin.

  1975cited by this paper
• The measurement of binding constants using circular dichroism. Binding of phenylbutazone and oxyphenbutazone.

  1970cited by this paper

• Suppression of Cancer Proliferation and Metastasis by a Versatile Nanomedicine Integrating Photodynamic therapy, Photothermal therapy, and Enzyme Inhibition.

  2020cites this paper
• Selective analysis of human serum albumin based on SEC-ICP-MS after labelling with iophenoxic acid

  2015cites this paper
• Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model.

  2013cites this paper
• Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin

  2011cites this paper
• QSRR: quantitative structure-(chromatographic) retention relationships.

  2007cites this paper
• Survey of the year 2003 commercial optical biosensor literature

  2005cites this paper
• Interaction of daunomycin antibiotic with human serum albumin: investigation by resonant mirror biosensor technique, fluorescence spectroscopy and molecular modeling methods.

  2005cites this paper
• Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction.

  2005cites this paper